Drugs / WH002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06513364 | Sep 2024 → Aug 2025 | breast cancer | Beijing Wehand-Bio Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WH002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06513364 ↗ |
| Route | Intravenous | “260 mg/m² administered intravenously on Day 1” NCT06513364 ↗ |